Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo shows promise for Tough-to-Treat uterine cancer

NCT ID NCT07594015

Recruiting now Disease control Sponsor: University of Miami Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This study tests two drugs, pembrolizumab and lenvatinib, in people with a type of uterine cancer that has come back after initial treatment. The cancer must be mismatch repair proficient, meaning it has a specific genetic feature. The goal is to see if this drug combination can shrink or stabilize the tumor. About 46 adults will take part.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT ENDOMETRIAL CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial carcinoma endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT ENDOMETRIAL CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Miami

    RECRUITING

    Miami, Florida, 33146, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.